MedPath

Maitland Mobilization and Scapular Stabilization Shoulder Dysfunction

Not Applicable
Completed
Conditions
Head and Neck Cancer
Registration Number
NCT06555913
Lead Sponsor
Cairo University
Brief Summary

Sixty patients from both genders suffering from shoulder disability post unilateral NDS (modified radical, selective) will participate in this study. Their ages will be ranged from 30 to 50 years. They will be selected randomly from Damanhur Oncology center, El-Behira, Egypt. They will be randomly distributed into three equal groups (each group 20 patients).

Detailed Description

Design of the study:

In this study the patients were randomly assigned into three equal groups (twenty patients for each group).

Group (A) :

This group included twenty patients suffering from shoulder disability following NDS (modified radical, selective). They received Maitland mobilization Technique and scapular stabilization exercises in addition to the traditional physical therapy program which included (ROM exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months.

Group (B):

This group included twenty patients suffering from shoulder disability following NDS (modified radical, selective). They received Maitland mobilization Technique in addition to the traditional physical therapy program which included (ROM exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months.

Group (C) :

This group included twenty patients suffering from shoulder disability following NDS (modified radical, selective). They received scapular stabilization exercises in addition to the traditional physical therapy program which include (ROM exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Patients' age will be ranged between 30-50 years.
  • Both genders will participate in this study.
  • All patients suffering from shoulder pain and disability following unilateral modified radical NDS or selective NDS.
  • All patients will begin the treatment program from 1 to 3 months after NDS.
  • All patients will have limited ROM of shoulder flexion, abduction, external rotation.
  • All patients enrolled to the study will have their informed consent.
Exclusion Criteria
  • Subjects with rotator cuff tears or other •shoulder ligament injuries.
  • Adhesive capsulitis secondary to Diabetes mellitus or fractures.
  • Recurrent shoulder dislocation.
  • Recent fracture or surgery to the shoulder.
  • Reflex sympathetic dystrophy.
  • Neurological disorder.
  • Epilepsy or any psychological disorders.
  • The presence of residual local-regional cancer or distant metastases to other regions.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Digital Goniometer2 months

Digital goniometer is a device which measures joint ranges, together with velocity and acceleration variables, with a high level of precision and at a relatively low-cost, practically similar to current analogical tools. The digital goniometer is a device specifically designed for the measurement of angles of movement of the human body with a resolution of 1°, representing an ideal substitute to traditional goniometers, which are usually based on a scale of 5° increments

Secondary Outcome Measures
NameTimeMethod
Shoulder Pain and Disability Index2 months

The shoulder pain and disability index (SPADI) is a self-report questionnaire developed to measure the pain and disability associated with shoulder pathology. The SPADI consists of 13 items in two subscales: pain (5 items) and disability (8 items), the original version has each item scored on a visual analogue scale (VAS) and a second version has items scored on a numerical rating scale (NRS)

Trial Locations

Locations (1)

Faculty of Physical Therapy

🇪🇬

Giza, Egypt

Faculty of Physical Therapy
🇪🇬Giza, Egypt

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.